Peter Q. Eichacker, M.D.
Critical Care Medicine Department
NIH Clinical Center
Building 10, Room 2C145
10 Center Drive
Bethesda, MD 20892
Dr. Eichacker's primary research interests have been the pathogenesis and treatment of septic shock, sepsis-induced lung injury related to commonly encountered types of bacteria as well as to the less-common anthrax bacterium, and anthrax-related cardiovascular injury. His research has provided critical insights into key factors influencing the effectiveness of immunomodulatory agents in the treatment of sepsis. This work has been taken into account by the US Food and Drug Administration (FDA) as it evaluates the potential application of new therapies for sepsis. Eichacker's research in the area of septic shock related to anthrax infection and the models he has developed to do that research with are unique and have provided insights not possible in other laboratories. This work has been instrumental in providing a basis for the inclusion of an anthrax toxin directed antibody therapy in the National Strategic Stockpile. Eichacker serves as a consultant to both NIAID and the FDA on issues pertaining both to the treatment of sepsis in general and anthrax in particular.
Dr. Eichacker is a Senior Investigator and Head of the Critical Care Medicine Section in the NIH Clinical Center's Critical Care Medicine Department (CCMD). He earned his undergraduate degree from Boston University and his medical degree from New York University. After he completed a residency and chief residency in internal medicine, he had a fellowship in pulmonary medicine at Bronx Municipal Hospital Center and Hospital of the Albert Einstein College of Medicine in New York. He joined NIH in 1986 as a CCMD fellow. In 1990 he was appointed Senior Investigator and Head of the Critical Care Medicine section in CCMD.
Cui X, Parent C, Macarthur H, Ochs SD, Gerstenberg E, Solomon S, Fitz Y, Danner RL, Banks SM, Natanson C, Salvemini D, Eichacker PQ. Severity of sepsis alters the effects of superoxide anion inhibition in a rat sepsis model. J Appl Physiol (1985). 2004;97(4):1349-57.
Cui X, Li Y, Moayeri M, Choi GH, Subramanian GM, Li X, Haley M, Fitz Y, Feng J, Banks SM, Leppla SH, Eichacker PQ. Late treatment with a protective antigen-directed monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis. J Infect Dis. 2005;191(3):422-34.
Solomon SB, Cui X, Gerstenberger E, Danner RL, Fitz Y, Banks SM, Natanson C, Eichacker PQ. Effective dosing of lipid A analogue E5564 in rats depends on the timing of treatment and the route of Escherichia coli infection. J Infect Dis. 2006;193(5):634-44.
Jaswal DS, Natanson C, Eichacker PQ. Endorsing performance measures is a matter of trust. BMJ. 2018;360:k703.
Pepper DJ, Jaswal D, Sun J, Welsh J, Natanson C, Eichacker PQ. Evidence Underpinning the Centers for Medicare & Medicaid Services' Severe Sepsis and Septic Shock Management Bundle (SEP-1): A Systematic Review. Ann Intern Med. 2018;168(8):558-568.
Related Scientific Focus Areas
Microbiology and Infectious Diseases
This page was last updated on September 9th, 2018